IL2 targeted to CD8+ T Cells promotes robust effector T-cell responses and potent antitumor immunity

Authors

Kelly D Moynihan, Asher Biotherapeutics, Inc.
Hussein Sultan, Washington University School of Medicine in St. Louis
Robert D Schreiber, Washington University School of Medicine in St. Louis
et al.

Journal

Cancer Discovery

Publication Date

7-1-2024

Volume

14

Issue

7

First Page

1206

Last Page

1225

Document Type

Open Access Publication

DOI

10.1158/2159-8290.CD-23-1266

Rights and Permissions

Moynihan KD, Kumar MP, Sultan H, Pappas DC, Park T, Chin SM, Bessette P, Lan RY, Nguyen HC, Mathewson ND, Ni I, Chen W, Lee Y, Liao-Chan S, Chen J, Schumacher TNM, Schreiber RD, Yeung YA, Djuretic IM. IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity. Cancer Discov. 2024 Jul 1;14(7):1206-1225. doi: 10.1158/2159-8290.CD-23-1266 This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. ©2024 The Authors; Published by the American Association for Cancer Research

Recommended Citation

Moynihan, Kelly D; Sultan, Hussein; Schreiber, Robert D; and et al., "IL2 targeted to CD8+ T Cells promotes robust effector T-cell responses and potent antitumor immunity." Cancer Discovery. 14, 7. 1206 - 1225. (2024).
https://digitalcommons.wustl.edu/oa_4/3884

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.